CEO letter to shareholders
Melbourne, Australia, 19 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read MoreInvestor Webinar transcript
Melbourne, Australia, 30 August 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read MoreCLINUVEL delivering on a long-term strategy with increase in annual revenues, profit
Melbourne, Australia, 29 August 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read MoreAnnual Results – Investor Webinar
Melbourne, Australia, 28 August 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read MoreAfamelanotide Significantly Reduces DNA Damage in a Healthy Population
CLINUVEL has been awarded a five-year contract by the U.S. Department of...
Read MoreSCENESSE® applied under five-year Veterans Affairs contract
CLINUVEL has been awarded a five-year contract by the U.S. Department of...
Read MoreCLINUVEL secures IP for melanocortins to treat central nervous system disorders
CLINUVEL has secured a family of patents and patent applications relating to...
Read MoreNews Kommuniqué III
Melbourne, Australia, 26 June 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read MoreTwilight Event - Briefing
CLINUVEL presented during a Twilight Briefing, after the close of market yesterday....
Read MoreNews Communiqué III
CLINUVEL’s News Communiqué III reviews the Company’s trajectory, and underlying reasons to...
Read MoreNews Kommuniqué II
Melbourne, Australia, 12 January 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read MoreNews Communiqué II
Download the PDF Authorised for ASX release by the Board of Directors...
Read MoreNews Communiqué I - Maestro Jaap van Zweden
Introducing CLINUVEL Intriguing Personality (CUVIP), Maestro Jaap van Zweden.
Read MoreCLINUVEL launches CYACÊLLE, Next Generation Solar Care
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More